Trandolapril

Trandolapril is a prodrug of an ACE inhibitor used to treat hypertension, congestive heart failure, and to improve survival following a myocardial infarction. Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications.

Chemical structure of Trandolapril
Mechanism
Curator reviewed
Primary indication
For the treatment of mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure (CHF), to improve survival following myocardial infarction (MI) in individuals who are hemodynamically stable and demonstrate symptoms...Curator reviewed · 5 structured indications
Formula / weight
C24H34N2O5 · 430.5372 g/mol (avg)
First approval
Canada, 2001 · United States, 1996
Code names
RU-44570
Brand names
  • Mavik
  • Tarka

Resolves to

Structure
InChIKeyVXFJYXUZANRPDJ-WTNASJBWSA-NSMILES[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O
Targets

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2TransportersSubstrate / inhibitor direction, not just membership
Listed above
1,261Drug interactionsStructured to mechanism, not free text
Sign in
21Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
197Marketed productsAcross 7 countries and 39 labellers
Sign in
2ATC codesIncluding every combination product, plus 14 drug categories
Sign in
24+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Trandolapril, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account